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Abstract
Introduction: The repair capability of traumatized articular cartilage is highly limited so that joint injuries often lead to
osteoarthritis. Migratory chondrogenic progenitor cells (CPC) might represent a target cell population for in situ
regeneration. This study aims to clarify, whether 1) CPC are present in regions of macroscopically intact cartilage from
human osteoarthritic joints, 2) CPC migration is stimulated by single growth factors and the cocktail of factors released
from traumatized cartilage and 3) CPC migration is influenced by cytokines present in traumatized joints.
Methods: We characterized the cells growing out from macroscopically intact human osteoarthritic cartilage using
a panel of positive and negative surface markers and analyzed their differentiation capacity. The migratory
response to platelet-derived growth factor (PDGF)-BB, insulin-like growth factor 1 (IGF-1), supernatants obtained
from in vitro traumatized cartilage and interleukin-1 beta (IL-1b) as well as tumor necrosis factor alpha (TNF-a) were
tested with a modified Boyden chamber assay. The influence of IL-1b and TNF-a was additionally examined by
scratch assays and outgrowth experiments.
Results: A comparison of 25 quadruplicate marker combinations in CPC and bone-marrow derived mesenchymal
stromal cells showed a similar expression profile. CPC cultures had the potential for adipogenic, osteogenic and
chondrogenic differentiation. PDGF-BB and IGF-1, such as the supernatant from traumatized cartilage, induced a
significant site-directed migratory response. IL-1b and TNF-a significantly reduced basal cell migration and
abrogated the stimulative effect of the growth factors and the trauma supernatant. Both cytokines also inhibited
cell migration in the scratch assay and primary outgrowth of CPC from cartilage tissue. In contrast, the cytokine IL-
6, which is present in trauma supernatant, did not affect growth factor induced migration of CPC.
Conclusion: These results indicate that traumatized cartilage releases chemoattractive factors for CPC but IL-1b and
TNF-a inhibit their migratory activity which might contribute to the low regenerative potential of cartilage in vivo.
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Introduction
Traumatic injuries of articular cartilage induce pathoge-
netic processes like chondrocyte death, matrix degrada-
tion and release of proinflammatory mediators [1], and
represent a major risk factor for the development of
osteoarthritis. Current surgical treatment options for
cartilage defects include microfracturing [2] and Pridie
drilling [3], which enable influx of blood and multipotent
mesenchymal stromal cells (MSC) from bone marrow,
and frequently end up in fibrocartilage, representing a
functionally inferior repair tissue. Strategies to improve
local recruitment of bone-marrow-derived MSC into
three-dimensional matrices are based on the migratory
potential of progenitor cells capable for chondrogenic
differentiation. An example already used in the clinic is
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the autologous matrix induced chondrogenesis (AMIC),
which combines microfracturing and a scaffold for
ingrowth of bone-marrow-derived MSC [4]. Such an
approach could possibly be enhanced by incorporation
and controlled release of chemoattractive factors for
MSC. Since classical chemokines induce parallel recruit-
ment of inflammatory cells the application of chemoat-
tractive growth factors may be most promising. In the
context of cartilage repair the chemoattractive properties
of platelet derived growth factor isoforms (PDGF), insulin
like growth factor 1 (IGF-1), basic fibroblast growth
factor (bFGF), bone morphogenetic proteins (BMPs) or
transforming growth factor beta 1 (TGF-b 1) for bone-
marrow-derived MSC could be of special interest [5-9].
However, it has been reported that subchondral drilling
leads to long-lasting alterations in microarchitecture and
bone mineral density of subchondral bone as well as for-
mation of intralesional osteophyts [10]. Therefore, in the
case of partial size defects, strategies to recruit CPC from
other tissue sources of a joint could be advantageous.
Besides bone marrow and trabecular bone [11], MSC-
like cells have been identified in synovial membrane [12],
synovial fluid [13,14], infrapatellar fat [15] and articular
cartilage itself [16-18]. These cell populations are not
identical but they fulfill a set of minimal criteria proposed
by the Mesenchymal and Tissue Stem Cell Committee of
the International Society for Cellular Therapy (ISCT) to
define human MSC [19]. Besides the adherence to plastic,
the expression of specific surface antigens is an important
criterion. As there is no single specific MSC marker, a
combination of positive and negative surface markers are
used to define MSC. According to ISCT, the minimal
panel of markers includes CD105, CD73 and CD90 but
excludes the hematopoietic markers CD45, CD34, CD14
(or CD11b), CD19 (or CD79a) and HLA class II [19].
Various additional positive and negative surface markers,
including Stro-1, MSCA-1, CD166, CD44, CD90, CD29,
CD54, CD9, CD146 and CD133, have been described
[15,20,21], which may help to develop a cell-surface anti-
gen profile for identification of MSC subpopulations. The
third criterion is the ability of MSC to differentiate
in vitro under lineage-specific culture conditions into
osteoblasts, adipocytes and chondrocytes first described
by Pittenger et al. [22].
The first studies on the presence of MSC-like cells in
normal and osteoarthritic human cartilage were based on
the characterization of enzymatically released cells
[16-18]. Recently, in digests of full thickness normal
human cartilage a progenitor cell population has been
identified based on the expression of a5-integrin and
characterized on clonal level [23]. Moreover, CPC were
described in the superficial layer of articular cartilage in
young calves [24]. It remained open whether cells with a
chondroprogenitor phenotype are able to leave their local
niche in cartilage actively. More recently, migratory CPC
have been described in late-stage human osteoarthritic
cartilage characterized by surface fissures and cell clus-
ters [25]. They grew out of tissue slices and may be
derived from breaks in the tidemark, express several
suface markers present on bone marrow derived MSC
and respond to serum or TGF-b3 by an increase in
migratory activity [25]. Moreover, Seol et al. recently
showed a repopulation of nonviable areas in damaged
cartilage by CPC derived from surrounding tissue in a
bovine in vitro cartilage trauma model [26]. Therefore,
CPC are discussed as a progenitor cell population suita-
ble for cartilage regeneration and some modulations of
CPC through application of growth factors, RUNX-2
knockdown or contemporary anti-inflammatory therapy
have been suggested to enhance their regenerative poten-
tial [27].
From this state of knowledge the questions arise
whether (i) migratory CPC are present in human cartilage
tissue representing an early stage of degeneration,
(ii) blunt traumatization of cartilage that is associated with
a loss of viable chondrocytes results in the release of che-
moattractive factors for human CPC and (iii) a local pro-
inflammatory milieu as observed after major joint injuries
influences their migratory potential. The proinflammatory
cytokine IL-1b, for example, may also have negative effects
on chondrogenic differentiation as the inhibition of IL-1b-
induced activation of NF-B was shown to facilitate chon-
drogenesis in a canine MSC differentiation model [28].
Therefore, the aims of the present study were to identify
and characterize mesenchymal stromal cells established by
spontanous outgrowth from macroscopically intact, non-
fibrillated osteoarthritic cartilage with a smooth surface,
which can be distinguished from ulcerated damaged tissue
in osteoarthritis [29]. The migration activity of the out-
grown cells was analyzed in response to distinct growth
factors (IGF-1 and PDGF-BB) as well as the cocktail of
factors released from human cartilage after in vitro trau-
matization. Furthermore, the influence of IL-1b and TNF-
a as the major pro-inflammatory cytokines released within
the joint after trauma and involved in the initiation and
progression of degenerative joint disease was investigated.
Our results show that macroscopically intact osteoar-
thritic cartilage contains migratory cells with a chondro-
progenitor phenotype and a very similar surface marker
profile compared to bone-marrow-derived MSC. Besides
single growth factors like IGF-1 and PDGF-BB, the combi-
nation of substances released by blunt traumatized carti-
lage effectively induced directed cell migration of CPCs
but the addition of IL-1b or TNF-a had detrimental
effects on migratory activity. This indicates that inflamma-
tory processes may have profound influence on local
chondroprogenitor cell recruitment for endogenous repair
of blunt cartilage injuries associated with a loss of viable
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cells or in situ regeneration of partial thickness cartilage
defects.
Methods
Cell isolation, cell culture and determination of
outgrowth activity
Multipotent MSC and CPC were isolated during routine
surgical procedures with informed consent of the
patients and in accordance with the terms of the Ethics
Committee of the University Ulm.
MSC were isolated from human bone marrow aspirates
(mean age 27, range 14 to 45 years) using a density gradi-
ent centrifugation (Biocoll separation solution: Biochrom
Seromed, Berlin, Germany) as described previously [7],
and cultured in basal medium consisting of DMEM with
10% fetal calf serum (FCS), 2 mM L-glutamine, and
100 U/ml penicillin/streptomycin (all Biochrom Seromed,
Berlin, Germany) at 37°C, 5% CO2 in 95% humidity. Cells
were split at a confluence of 80%.
CPC were obtained from the resected tissue of 71
patients with osteoarthritis undergoing total knee repla-
cement (mean age 67, range 45 to 87 years) according
to Koelling et al. [25]. In brief, cartilage slices with an
edge length of about 4 mm were cut from macroscopi-
cally intact, non-fibrillated regions and placed in a cul-
ture dish with basal medium. Patients with systemic
inflammatory diseases, such as rheumatoid arthritis or
spondylarthropathies, were excluded. After outgrowth
from cartilage tissue, CPC were expanded and cultured
like MSC. For cytokine studies, 1 ng/ml IL-1b and
10 ng/ml TNFa (both tebu-bio, Offenbach, Germany),
respectively, were added to the medium and renewed
every two to three days. To determine the outgrowth
activity after 14 days of cultivation, emigrated cells were
trypsinized after the removal of cartilage slices and
counted by trypan blue exclusion staining using a Neu-
bauer chamber.
Immunocytochemistry
To analyze freshly emigrated CPC, cartilage slices were
directly placed in four-chamber culture slides (BD Pharmin-
gen, San Diego, CA, USA). After outgrowth, the tissue slices
were removed and the CPC used for immunocytology.
Otherwise, CPC were cultured on culture slides in passage
3 or 4. The cells were washed and fixed with 4% formalde-
hyde, incubated with primary antibodies overnight at 4°C
(CD90, CD54, CD166: Acris, Hiddenhausen Germany;
CD73: AbD Serotec, Düsseldorf, Germany; Cadherin:
Life Technologies, Darmstadt, Germany) and stained with
the DAKO LSAB™2 Kit (Hamburg, Germany). The cytos-
keleton of CPC was visualized by actin-labeling with Phal-
loidin-FITC (Sigma-Aldrich, Taufkirchen, Germany),
Vinculin-labeling with a specific primary antibody (Sigma-
Aldrich) and a secondary Alexa Fluor 488-coupled antibody
(Life Technologies) and counterstained with DAPI (Sigma).
Flow cytometry analysis
Cultured cells in passage 3 or 4 were detached using a
trypsin/EDTA solution (Biochrom Seromed, Berlin,
Germany) and incubated with antibodies against the sur-
face markers and the species-matched isotype controls for
30 minutes in the dark on ice. In the case of biotinylated
antibodies (CD44 Biotin), cells were washed with PBS
before adding PerCP Streptavidin. The samples were char-
acterized by single- and four-color immunofluorescence
and 1 × 104 cells were analyzed on a Becton Dickinson
FACSCalibur flow cytometer (BD Biosciences, Heidelberg,
Germany) with dual-laser technology. The CellQuest soft-
ware V. 5 from Becton Dickinson was used for analysis.
The amount of positive cells was calculated as a percen-
tage in comparison to the isotype control. A maximum of
1% positive cells by staining with the isotype control were
allowed. CD146 and IgG2a were obtained from R&D Sys-
tems (Minneapolis, MN, USA), CD133 was obtained from
Miltenyi Biotec (Bergisch Gladbach, Germany) and
MSCA-1, Stro-1 and IgM were obtained from BioLegend
(San Diego, CA, USA). All other antibodies were provided
by BD Pharmingen (Heidelberg, Germany).
Differentiation assays
After cultivation of CPC in basal medium until 80%
confluence, cells were cultivated in differentiation media
or basal medium for control for up to four weeks as
described for MSC [17,30]. The adipogenic medium
consisted of basal medium with 0.5 μmol/l dexametha-
sone, 0.5 μmol/l isobutylmethylxanthine and 50 μmol/l
indomethacin. The osteogenic medium consisted of
basal medium with 0.1 μmol/l dexamethasone, 50 μg/ml
ascorbic acid and 200 μg/ml b-glycerophosphate. For
chondrogenic differentiation in micromass culture, 2 ×
105 CPC were pelleted by centrifugation and cultivated
in chondrogenic medium consisting of DMEM and
Ham’s F-12 with 4.5 g/l glucose, 100 U/ml penicillin/
streptomycin, 40 ng/ml L-proline, 0,1 μmol/l dexa-
methasone, 50 μg/ml ascorbic acid supplemented with
TGF-b3 (10 ng/ml), BMP-6 (10 ng/ml) and 10 μl/ml
ITS+ (Sigma). The differentiation was confirmed by his-
tological staining.
The von Kossa and Oil Red staining was performed as
previously described [17]. Alkaline phosphatase activity
was estimated with the Leukocyte Alkaline Phosphatase
Kit (Sigma-Aldrich, Taufkirchen, Germany) as pre-
scribed by the manufacturer. The immunostaining was
performed on paraffin-embedded tissue sections with
collagen II antibody (Acris, Hiddenhausen, Germany)
and cartilage oligomeric matrix protein (COMP)
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antibody (kindly provided by Dr. Zaucke, Köln,
Germany) and the DAKO LSAB™2 Kit (Hamburg,
Germany).
Chemotaxis and attachment assay, growth factors,
cytokines and supernatant of cartilage tissue culture
Chemotaxis assays were performed with recombinant
human (rh) PDGF-BB (BioLegend, Fell, Germany,
10 ng/ml), rhIGF-1 (Biomol, Hamburg, Germany,
100 ng/ml), IL-1b (tebu-bio, 0.1 to 10 ng/ml), TNFa
(tebu-bio, 1 to 100 ng/ml) and IL-6 (Biomol, 1 ng/ml).
Additionally, serumfree supernatant of untraumatized and
traumatized cartilage explants of four donors (mean age
66, range 62 to 70 years) was used. The tissue was pre-
pared and treated as described elsewhere [31]. In brief,
full-thickness explants were harvested from well-preserved
cartilage of donors undergoing total knee joint replace-
ment due to osteoarthritis. The cartilage was traumatized
by an impact load of 0.59 J using a drop-tower device and
cultivated in serum-free medium for 24 h, unimpacted
explants of the same patients served as control. The super-
natant was harvested and stored at -80°C until use.
Cell migration was analyzed by a modified Boyden
chamber assay, using a 48-well microchemotaxis chamber
(NeuroProbe Inc., Baltimore, MD, USA) with polycarbo-
nate filters with 8 μm pores (NeuroProbe Inc.) as pre-
viously described [5]. MSC and CPC were trypsinized and
suspended in serum-free DMEM. Growth factors were
diluted in serum-free DMEM, filled into the lower com-
partment of the chemotaxis chamber and covered with the
chemotaxis filter. The upper wells were loaded with 50 μl
cell suspension (1 × 104 cells) and incubated for four
hours at 37°C, 5% CO2 in 95% humidity. The filter was
taken off, washed with PBS and scraped with a rubber
wiper to remove the non-migrated cells on the upper side
of the filter. The migrated cells on the lower side were
fixed with 4% formaldehyde, stained with Giemsa solution
(Merck, Darmstadt, Germany) and counted. DMEM in the
lower well served as a negative control (basal migration)
for each experiment. The results were determined as the
total number of migrated cells.
To distinguish chemotaxis from undirected chemokin-
esis migration analyses with the growth factors, superna-
tants of cartilage tissue and cytokines were performed in
the presence and absence of a concentration gradient [32].
For the attachment assay on the polycarbonate filters,
5 × 102 CPC in 50 μl serum-free DMEM were given into
the upper well of the Boyden chamber and incubated for
30 and 60 minutes. Adherent cells on the upper side of the
filter were fixed, stained and counted as described above.
Scratch assay
CPC were grown to a confluent monolayer. After mak-
ing a “scratch” in the cell layer with a 200 μl pipette tip,
CPC cultures were rinsed gently to discard debris. The
cells were cultivated in basal medium with or without
cytokines (1 ng/ml IL-1b and 10 ng/ml TNFa, respec-
tively) for 48 h, the medium was renewed after 24 h.
Migration was documented by phase contrast microscopy.
Statistical analysis
All experiments were analyzed using GraphPad Prism
version 5.0d (GraphPad Software, San Diego, CA, USA).
For statistical analysis a Student’s t-test or one-way
ANOVA was used with Bonferroni multiple comparison
post-test. A P < 0.05 was considered significant (*).
Other levels of significance were defined as follows: P <
0.01 (**) and P < 0.001 (***).
Results
CPC cultures could be established by spontanous out-
growth from macroscopically intact cartilage of 97% of
patients with knee osteoarthritis. The first cells were
visible after 5 to 10 days and they had a fibroblastoid
morphology. Figure 1 depicts freshly emigrated CPC (A)
and their positive staining for the typical MSC surface
markers CD73, CD90, CD166 and CD54 (B-F) in
immunocytochemistry.
Characterization of MSC and CPC by immunocytology
Due to the lack of a specific single surface marker protein
for MSC, we used variable combinations of different mar-
kers for flow cytometric analysis to characterize the iso-
lated MSC and CPC. MSC from bone marrow and CPC
grown out from cartilage were stained with single mar-
kers (see Figure S1 in Additional file 1). CPC expressed
similar levels of CD29, CD44, CD73, CD90 (all >90%),
CD105 and CD166 (>75%), CD54 and MSCA-1 (44 to
66%), Stro-1 (16 to 23%) and CD88 (9 to 10%) as bone
marrow-MSC. Significantly different levels of expression
were only observed for CD9 (MSC: 46.7 ± 4.3% mean ±
standard error of positive cells, CPC: 80.7 ± 3.5%) and
CD146 (MSC: 44.0 ± 6.8%, CPC: 11.9 ± 2.3%). CPC and
MSC were negative for the hematopoietic stem cell mar-
kers CD34 and CD133, the lymphocyte marker CD45
and Octamer-binding transcription factor (Oct-3/4).
CD14 and CXC chemokine receptor 4 (CD184) were
only slightly expressed (<4%).
A combination of the above-mentioned markers was
used to characterize both cell types in more detail. We
investigated 25 different quadruplicate marker combina-
tions (Figure 2 and Figure S2 in Additional file 2) and
compared the expression profiles between MSC and
CPC. Statistical analysis showed significant differences
in two marker combinations (Figure 2; arrows): 2.14 ±
0.8% of the MSC and 14.62 ± 7.1% of the CPC
expressed CD45-/CD166/CD9/Stro-1 (P = 0.003; n ≥ 6)
and 25.27 ± 7.1% of the MSC and 4.95 ± 2.3% of the
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CPC expressed CD105/CD34-/CD9/MSCA-1 (P = 0.016;
n = 7). The other 23 combinations showed no signifi-
cant differences between MSC and CPC.
A characterization of CPC concerning adhesion recep-
tors and the actin cytoskeleton revealed a strong expres-
sion of the integrin subunits a1, a5 and b1 (>80%
positively stained cells, a1 and a5: see Figure S3A in Addi-
tional file 3; b1 (CD29): see Figure S1 in Additional file 1)
and a partial expression of a2 and a6 (8.5% and 23.9%
positively stained cells, respectively, see Figure S3A in
Additional file 3) in flow cytometry. CPC cultured in
monolayer stained positive for Cadherin 11 and showed
the formation of actin stress fibers as well as vinculin-
staining at focal adhesion sites in immunocytochemical
staining (Figure S3B, C in Additional file 3).
Differentiation potential of CPC
CPC were seeded either in monolayer (adipogenic,
osteogenic) or 3D micromass culture (chondrogenic) to
examine their multipotent differentiation potential. We
induced adipogenesis, osteogenesis and chondrogenesis
for four weeks and confirmed the differentiation by PCR
gene expression of respective marker genes (LPL/leptin
for adipogenic, Runx2/ALPL/osteocalcin for osteogenic,
SOX9/COL2A1/ACAN/COMP/COL10A1 for chondro-
genic differentiation, see Figure S4 in Additional file 4)
and histological staining. Cells cultured in basal medium
over four weeks were used as control.
The adipogenic differentiation of CPC is shown in
Figure 3A. We could observe the formation of cell
colonies that contained lipid vacuoles which were posi-
tive for Oil Red O. The majority of cells, however, did
not develop lipid droplets comparable to the negative
control cultivated with basal medium. CPC showed adi-
pogenic differentiation to a lesser extent than MSC ana-
lyzed in parallel (data not shown), indicating that only a
subpopulation of the CPC exhibits adipogenic potency.
CPC were also cultured for four weeks with osteo-
genic medium and were stained with von Kossa and for
alkaline phosphatase to investigate the osteogenic poten-
tial. Figure 3B shows black calcium deposits after von
Kossa staining. Further staining for AP (alkaline phos-
phatase), one of the early marker in osteogenesis,
showed in the presence of osteogenic supplements dif-
fuse, red dye deposit as a measurement of AP activity
(Figure 3C). In control wells these deposits could not be
detected. Gene expression of osteocalcin was strong
after osteogenic differentiation, but could as well be
weakly detected in undifferentiated cells (Figure S4 in
Additional file 4). A faint staining of osteocalcin could
partly be detected in undifferentiated CPC in monolayer
by immunocytology (data not shown).
To analyze if CPC can be differentiated into chondro-
cytes, cultivation was performed as micromass pellet
culture. After cultivation with chondrogenic medium
over four weeks, the matrix stained positive for COMP
(Figure 3D) and collagen type II (Figure 3E) indicating
chondrogenic differentiation. In the absence of chondro-
genic factors, there was no positive staining for these
matrix proteins of cartilage.
Figure 1 Freshly outgrown CPC were characterized morphologically and by immunocytochemical stainings. A: Cartilage slice after
11 days of cultivation with emigrated cells of fibroblastoid appearence. B-F: Immunocytochemical staining of chondrogenic progenitor cells
(CPC) specific for CD73 (B), CD90 (C), CD166 (D) and CD54 (E); F: negative control. The bar indicates 100 μm.
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Chemotaxis assay
Cell migration of CPC was significantly stimulated by
10 ng/ml PDGF-BB and 100 ng/ml IGF-1 as shown in
Figure 4. Furthermore, serum-free conditioned medium
of human osteoarthritic cartilage samples significantly
stimulated CPC migration. Supernatant from cartilage
injured in vitro by a defined blunt trauma led to a
further significant increase in the number of migrated
cells (Figure 4). The stimulation of cell migration was
only present in case of a concentration gradient (data
not shown), indicating that in all cases site-directed
migration (chemotaxis) was induced and not random
migration (chemokinesis).
In contrast to the observed chemotaxis towards PDGF-
BB, IGF-1 and the supernatant of traumatized cartilage, a
gradient of IL-1b or TNF-a led to profound and highly
significant inhibition of CPC-migration over a broad con-
centration range (IL-1b from 0.1 to 10 ng/ml, TNF-a
from 1 to 100 ng/ml) as shown in Figure 5. Exemplarily,
it could be shown that both cytokines also inhibited CPC
migration when they were present in the upper and
lower compartment without concentration gradient (data
not presented).
To test a possible interference with chemoattractive
effects of single growth factors, we analyzed the effects of
PDGF-BB and IGF-1 without and with parallel gradients
of IL-1b and TNF-a. The results clearly showed that
1 ng/ml IL-1b or 10 ng/ml TNF-a completely abrogated
the stimulatory effect of these growth factors (Figure 6).
An inhibition below basal levels (medium alone) was also
found exemplarily when the cytokines were present
homogenously in the upper and lower compartment
(data not shown). Moreover, the powerful chemotactic
effect of the factor cocktail released by in vitro trauma-
tized cartilage was significantly inhibited to basal levels,
but not below that value as observed with PDGF-BB or
IGF-1 co-application (Figure 6). An attachment assay
with the migration filters indicated that respective
Figure 2 Marker expression profiles from MSC and CPC. Both cell types were respectively stained with four markers in different
combinations. The percentage of quadruple stained cells is depicted on the y-axis. Due to the varying patient collectives the number of
different donors is declared as n (range). The arrows highlight the marker combinations which showed significance in Student’s t-test: CD45-/
CD166/CD9/Stro-1 (P = 0.003), CD105/CD34-/CD9/MSCA-1 (P = 0.019). CPC, chondrogenic progenitor cells; MSC, mesenchymal stromal cells.
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Figure 3 Differentiation potential of CPC. Cells were cultured with basal medium as control (left column) or with differentiation medium
(adipogenic, osteogenic, chondrogenic) for up to four weeks. Chondrogenic progenitor cells (CPC) are A: Oil Red O positive after adipogenic
differentiation (red: stained lipid droplets) and positive after osteogenic differentiation for B: von Kossa (black: mineral deposition) and C: alkaline
phosphatase (AP) activity (red dye deposit). The chondrogenic differentiation was performed as 3D micromass culture (D-E).
Immunohistochemical staining with cartilage oligomeric matrix protein (COMP; D) and collagen II (Col II; E) were positive. The bar indicates
100 μm unless otherwise noted.
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concentrations of IL-1b and TNF-a had no influence on
the number of adherent CPC after 30 and 60 minutes
(data not shown). IL-6, which is increased (to about 1 ng/
ml) in supernatants of traumatized cartilage [31] did not
affect basal or PDGF-stimulated CPC migration at 1 ng/
ml (Figure S5 in Additional file 5).
Scratch assay and primary outgrowth in the presence of
IL-1b and TNF-alpha
We next performed a commonly used wound-healing
assay, also called a scratch assay, to determine the influ-
ence of IL-1b and TNF-a on cell migration in an injury-
induced environment over a period of 48 h. Figure 7
shows that CPC infiltrated the gap after 24 h and nearly
closed it after 48 h under control conditions. In contrast,
the addition of 1 ng/ml IL-1b almost abrogated and of
10 ng/ml TNF-a strongly slowed down cell migration in
the observation period.
The same cytokines and concentrations were used to
investigate the influence of pro-inflammatory stimulation
on the primary outgrowth activity of CPC from cartilage
slices. The number of outgrown cells after 14 days of culti-
vation averaged 1,800 cells/well under control conditions
whereas addition of IL-1b (1 ng/ml) or TNF-a (10 ng/ml)
both reduced outgrowth to less than 10 cells/well on aver-
age (Figure S6 in Additional file 6).
Discussion
In agreement with previous studies we found that
human articular cartilage contains a cell population that
is characterized by a primary mesenchymal progenitor
phenotype or acquires this phenotype during in vitro
expansion [16-18,23,33,34]. A principle difference from
Figure 4 Effects of PDGF, IGF and cartilage supernatant on CPC
migration. The number of migrated cells without stimulation and
stimulated with platelet-derived growth factor (PDGF) (10 ng/ml),
IGF (100 ng/ml) or supernatant of unimpacted cartilage (supernatant
(SN) ∅ trauma) and impacted cartilage (SN trauma), respectively, are
depicted. The values represent the mean ± SEM with n ≥3.
Statistical significance was evaluated by ANOVA followed by a
Bonferroni multiple comparison post-test with *P < 0.05, **P < 0.01
and ***P < 0.001.
Figure 5 Dose-dependent effects of IL-1b and TNF-a on basal
migration of CPC. Cells were analyzed in basal medium with and
without addition of interleukin (IL)-1b and tumor necrosis factor
(TNF)-a in the indicated concentrations. The values represent the
mean ± SEM with n ≥3. Statistical significance was evaluated by
ANOVA followed by a Bonferroni multiple comparison post-test with
*P < 0.05, **P < 0.01 and ***P < 0.001. CPC, chondrogenic
progenitor cells.
Figure 6 Effects of IL-1b and TNF-a on stimulated migration of
CPC. Chondrogenic progenitor cells CPC migration was stimulated
with platelet-derived growth factor (PDGF) (10 ng/ml), IGF (100 ng/ml)
or supernatant of impacted cartilage (supernatant (SN) trauma) and
inhibited with interleukin (IL)-1b (1 ng/ml) and tumor necrosis factor
(TNF)-a (10 ng/ml), control cells remained unstimulated. The values
represent the mean ± SEM with n ≥3. Statistical significance was
evaluated by ANOVA followed by a Bonferroni multiple comparison
post-test with *P < 0.05, **P < 0.01 and ***P < 0.001.
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most previous experimental approaches is that we estab-
lished the cell cultures by active outgrowth and not by
enzymatic digestion, which selects for cells with migra-
tion potential. This approach was first used by Kölling
et al. [25], who described migratory CPC in end-stage
fibrillated cartilage with breaks in the subchondral bone
plate allowing ingrowth of blood vessels. Their observa-
tion is in agreement with the hypothesis that the pre-
sence of cells with characteristics of MSC in adult
vascularized tissues may be based on a common perivas-
cular origin [35]. We identified and characterized out-
growing cells with a CPC phenotype in macroscopically
intact cartilage from osteoarthritic joints representing an
early stage of tissue degeneration. Although single breaks
in the subchondral bone plate cannot be excluded, rather
our results support the concept that mesenchymal pro-
genitor cells may be otherwise present in cartilage. The
developmental origin of these cells and the influence of
the osteoarthritic process still remain to be elucidated.
The surface marker profile of outgrowing cells proved to
be identical to previous studies on enzymatically digested
and culture expanded cells from human articular cartilage
[16-18,23] and to cells obtained by outgrowth from
severely degenerated osteoarthritic cartilage [25] or normal
bovine cartilage [26]. A direct comparison of 18 single sur-
face markers with bone-marrow derived MSC revealed
significant differences only for CD9 and CD146, which
may be based on replicative senescence of CPC during
proliferation after outgrowth since an increase in CD9 and
a decrease in CD146 has been observed in higher passages
of bone-marrow-derived MSC [36]. CD146 is a surface
marker of pericytes and expressed on a population of bone
marrow derived subendothelial cells for which true self-
renewing capacity was described [37]. Therefore, its lower
expression may also relate to the origin from a primary
avascular tissue. The surface marker analysis of 25 differ-
ent quadruplicate marker combinations going far beyond
existing data on CPC did not reveal much difference in
comparison to bone-marrow-derived MSC, indicating a
major overlap of subpopulations. Flow-cytometric integrin
analyses showed strong expression of the integrin subunits
a5 and b1 and a partial expression of a2 and a6 in accor-
dance with previous studies [25]. The presence of the fibro-
nectin receptor (a5/b1) is in line with the identification of a
Figure 7 CPC migration analyzed by scratch assay. Confluent chondrogenic progenitor cells (CPC) were scratched, incubated with or without
interleukin (IL)-1b (1 ng/ml) or tumor necrosis factor (TNF)-a (10 ng/ml) and documented by phase contrast microscopy after the indicated time
points. The bars indicate 200 μm. Representative pictures of four independent experiments are shown.
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cartilage progenitor population differentially isolated by
fibronectin binding [23]. Differentiation analysis under line-
age-specific conditions confirmed the potential for chon-
drogenic, osteogenic and adipogenic differentiation known
from other studies on cartilage derived progenitor cells
[16-18,23]. An only partial development of lipid droplets in
adipogenic differentiation observed in our study is also
described in the literature and may be due to inhibitory fac-
tors from preadipocytes [16]. The observation of slight
osteocalcin expression in undifferentiated CPC may be
ascribed to their osteoarthritic origin [38]. The absence of
differentiation and marker gene expression without lineage-
specific induction supports the progenitor status of CPC.
As described for bone-marrow-derived MSC, chondrogenic
differentiation with TGF-b3 was associated with the induc-
tion of collagen type × on RNA-level [39], indicating
further similarity.
From a clinical point of view, migratory chondropro-
genitor cells of cartilage are of interest for novel strategies
to improve cell recruitment into cartilage defects without
perforation of the subchondral bone plate and to support
endogenous repair of blunt injured cartilage as a compen-
sation for trauma-induced chondrocyte loss. Local applica-
tion of PDGF-BB and IGF-1 has been suggested as a
promising strategy for induction of cartilage repair. Posi-
tive effects could be expected from stimulation of prolif-
eration as well as proteoglycan synthesis of chondrocytes
and reduction of proteoglycan degradation [40]. Further-
more, these growth factors were described to act as an
anti-inflammatory agent by inhibiting IL-1b-mediated NF-
B-signalling and apoptosis [41]. We found that both
growth factors also stimulated site-directed migration of
CPC in vitro - as previously reported for bone-marrow
derived MSC [5,6]. Possibly this biological functionality
may contribute to enhanced repair of cartilage defects in
vivo by transplantation of chondrocytes overexpressing
IGF-1 [42]. The cocktail of factors released from full thick-
ness cartilage explants generated by sharp excision was
also chemoattractive for CPC and an additional blunt
injury leading to necrosis or apoptosis of about half of the
chondrocytes [31] increased this cell-biologic function sig-
nificantly. In our cartilage trauma model, the cytokine IL-
6 is released, leading to a concentration of about 1.8 ng/ml
after 24 h [31]. The migration assays with up to 10 ng/ml
IL-6, however, neither showed a positive nor negative
effect on migratory activity of CPC. A profiling of proteins
released by cartilage in response to mechanical compres-
sion injury [43,44] identified potential candidates for
chemoattractive effects like fibronectin, CTGF and osteo-
pontin, which have been shown to be involved in MSC
migration [45-47] and may contribute to the activating
effect of the supernatant on CPC in its complex composi-
tion. A recent study on bovine cartilage indicated that the
release of high mobility group box chromosomal protein
1 (HMGB-1) and receptor for advanced glycation end pro-
duct (RAGE)-mediated processes partly explains the che-
motactic effect [26].
Though CPC have the capacity to actively leave their
original niche and to invade cartilage tissue [25], the
recruitment of CPC after trauma in vivo seems to be low,
indicated by reduced cell density at the site of a preced-
ing trauma [48]. An interference of the proinflammatory
cytokines IL-1b and TNF-a, which are secreted from
synovial cells and increase in synovial fluid early after the
injury of a joint [49] could account for this effect. In con-
trast to IL-6, these cytokines had detrimental effects on
CPC migration and abrogated the effect of PDGF-BB,
IGF-1, as well as trauma supernatants. In the Boyden
chamber assay this effect was present with and without
concentration gradient of the cytokines indicating that
basic mechanisms of cell migration like adhesion pro-
cesses, MMP-synthesis and - activation as well as cytos-
keletal reorganization may be negatively affected. In the
experimental setting, negative effects on CPC adhesion
could not be observed. In human chondrocytes, however,
it was shown that IL-1b interferes with F-actin structures
and other cytoskeletal components [50], which might
impair cell motility as the cytoskeleton is known to play a
pivotal role in cell movement. The inhibitory effects of
IL-1b and TNF-a were confirmed in a scratch assay
which allows observation of cell migration in an injury-
induced environment [51], supporting the assumption of
biological relevance. Finally, the primary outgrowth of
CPC from their cartilage origin was markedly impaired
by both cytokines, indicating that these pro-inflammatory
factors also inhibit the process of release from the native
environmental niche which is not defined so far. The
migration analyses used covered different time spans
from 4 h (Boyden Chamber) to 14 days (outgrowth)
which shows that the inhibitory effect is not compensated
over an extended period. These findings may also suggest
a role for IL-1b and TNF-a in osteoarthritis that was
unaccounted for so far. Besides promoting the phenoty-
pic shift of chondrocytes and cartilage destruction [52],
an impairment of CPC recruitment could compromise
the ability of endogenous repair.
Conclusions
Overall, these results may be relevant for processes of
endogenous cartilage repair after blunt traumatization
and, in a broader context, for the pathogenesis of osteoar-
thritis in general. They also encourage approaches towards
in situ regeneration of cartilage defects based on local
recruitment of chondroprogenitor cells. For transfer into
novel therapeutic strategies, further questions have to be
addressed: in case of a cartilage defect, matrices enabling
CPC ingrowth have to be defined. We have observed an
active outgrowth into a collagen type I hydrogel matrix
Joos et al. Arthritis Research & Therapy 2013, 15:R119
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(unpublished results) and similar results have been
observed for PGA/PLA or PGA/PCL scaffolds [53]. The
chondrogenic differentiation potential of CPC including
interindividual variation, effect of cytokines [54], influence
of aging, osteoarthritis and, as recently published, gender-
related aspects like exposure to estrogen in women or tes-
tosteron in men [55] clearly need further investigation.
The present study indicates that with respect to CPC
recruitment, control of inflammatory processes is an
important aspect that should be taken into consideration.
Additional material
Additional file 1: Figure S1: Flow cytometric analysis of MSC (black)
and CPC (gray) marker expression. Open histograms represent marker-
specific antibodies. Gray shaded histograms represent isotype control.
CPC: chondrogenic progenitor cells; MSC: mesenchymal stromal cells.
Additional file 2: Figure S2: Marker expression profiles from MSC
and CPC. Both cell types were respectively stained with four markers in
different combinations. The percentage of quadruple stained cells is
depicted on the y-axis. Due to the varying patient collectives the
number of different donors is indicated as n (range). CPC: chondrogenic
progenitor cells; MSC: mesenchymal stromal cells.
Additional file 3: Figure S3: Flow cytometric and
immunocytochemical analysis of CPC adhesion receptors and
cytoskeleton expression. A: Flow cytometric analysis of the integrin
subunits a1, a2, a5 and a6. Open histograms represent marker-specific
antibodies. Gray shaded histograms represent isotype control.
Representative histograms of two independent experiments are shown.
B: Cadherin-11 specific staining of chondrogenic progenitor cells (CPC).
C: Fluorescence staining of actin stress fibers by Phalloidin-FITC (green),
of Vinculin by immunocytology (red) and of the nuclei by DAPI (blue)
in CPC.
Additional file 4: Figure S4. Differentiation status of CPC before (t0) and
after cultivation in basal (BM), adipogenic (AD), osteogenic (OD) or
chondrogenic (CD, micromass culture) differentiation media for four
weeks. A: Adipogenic differentiation: (1) house-keeping gene GAPDH; (2)
lipoprotein lipase; (3) leptin. B: Osteogenic differentiation: (1) GAPDH; (2)
alkaline phosphatase; (3) Osteocalcin; (4) runt-related transcription factor
2. C: Chondrogenic differentiation: (1) GAPDH; (2) collagen type II; (3)
collagen type X; (4) cartilage oligomeric matrix protein; (5) aggrecan; (6)
Sry-related HMG box (SOX9). CPC: chondrogenic progenitor cells.
Additional file 5: Figure S5: Effects of IL6 and PDGF on CPC
migration. The number of migrated cells without stimulation and
stimulated with platelet-derived growth factor (PDGF) (10 ng/ml) and/or
IL6 (1 ng/ml) is depicted. The values represent the mean ± SEM with n =
3. Statistical significance was evaluated by ANOVA followed by a
Bonferroni multiple comparison post-test with *P < 0.05, **P < 0.01 and
***P < 0.001. CPC: chondrogenic progenitor cells.
Additional file 6: Figure S6: Effects of IL-1b and TNF-a on CPC
outgrowth. The number of outgrown cells without stimulation (Control)
and stimulated with interleukin (IL)-1b (IL, 1 ng/ml) or tumor necrosis
factor (TNF)-a (TNF, 10 ng/ml) is depicted in log scale. The values
represent the mean ± SEM with n = 4. CPC: chondrogenic progenitor
cells.
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